With 5.56 million shares changed hands, the volume of the stock remained lighter than its average volume of 18.14 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $0.4627 whereas the lowest price it dropped to was $0.39. The 52-week range on RSLS shows that it touched its highest point at $29.00 and its lowest point at $0.30 during that stretch. It currently has a 1-year price target of $58.00. Beta for the stock currently stands at 1.45.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RSLS was up-trending over the past week, with a rise of 16.19%, but this was up by 10.75% over a month. Three-month performance dropped to -88.15% while six-month performance fell -92.28%. The stock lost -95.66% in the past year, while it has lost -90.57% so far this year.
Float and Shares Shorts:
At present, 11.28 million RSLS shares are outstanding with a float of 9.24 million shares on hand for trading. On 2025-04-15, short shares totaled 1.04 million, which was 919.9999999999999 higher than short shares on 1741910400. In addition to Mr. Dan W. Gladney as the firm’s Executive Chair, Mr. Paul F. Hickey serves as its CEO, President & Director.
Institutional Ownership:
Through their ownership of 0.04877 of RSLS’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RSLS since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$26.1 being high and -$26.1 being low. For RSLS, this leads to a yearly average estimate of -$26.1.
